Kenneth C. Anderson

167.4k total citations · 22 hit papers
1.4k papers, 76.9k citations indexed

About

Kenneth C. Anderson is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kenneth C. Anderson has authored 1.4k papers receiving a total of 76.9k indexed citations (citations by other indexed papers that have themselves been cited), including 1.0k papers in Hematology, 872 papers in Molecular Biology and 527 papers in Oncology. Recurrent topics in Kenneth C. Anderson's work include Multiple Myeloma Research and Treatments (971 papers), Protein Degradation and Inhibitors (393 papers) and Peptidase Inhibition and Analysis (252 papers). Kenneth C. Anderson is often cited by papers focused on Multiple Myeloma Research and Treatments (971 papers), Protein Degradation and Inhibitors (393 papers) and Peptidase Inhibition and Analysis (252 papers). Kenneth C. Anderson collaborates with scholars based in United States, France and Italy. Kenneth C. Anderson's co-authors include Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Noopur Raje, Constantine S. Mitsiades, Klaus Podar, Yu‐Tzu Tai, Antonio Palumbo and Robert Schlossman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Kenneth C. Anderson

1.4k papers receiving 75.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple myeloma

2000 1.8k citations Noopur Raje, Kenneth C. Anderson profile →
Multiple Myeloma

2011 1.7k citations Kenneth C. Anderson et al. profile →
Multiple myeloma

2017 755 citations Kenneth C. Anderson et al. profile →
NF-κB as a Therapeutic Target in Multiple Myeloma

2002 752 citations Teru Hideshima, Dharminder Chauhan et al. profile →
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

2010 746 citations Yu‐Tzu Tai, Kenneth C. Anderson et al. profile →
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

2001 740 citations Noopur Raje, Teru Hideshima et al. profile →
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

2000 708 citations Teru Hideshima, Dharminder Chauhan et al. profile →
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

2007 702 citations Teru Hideshima, Constantine S. Mitsiades et al. profile →
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

2013 645 citations Aldo M. Roccaro, Antonio Sacco et al. profile →
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

2002 630 citations Paul G. Richardson, Robert Schlossman et al. profile →
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

1998 610 citations Kenneth C. Anderson et al. profile →
Molecular sequelae of proteasome inhibition in human multiple myeloma cells

2002 597 citations Nicholas Mitsiades, Dharminder Chauhan et al. profile →
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

2003 575 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. profile →
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

2004 569 citations Paul G. Richardson, Kenneth C. Anderson et al. profile →
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

2005 560 citations Dharminder Chauhan, Klaus Podar et al. profile →
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

2002 544 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. profile →
Multiple myeloma

2009 533 citations Marc S. Raab, Klaus Podar et al. profile →
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

2012 488 citations Loredana Santo, Teru Hideshima et al. profile →
Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

2014 375 citations Yu‐Tzu Tai, Andrew L. Kung et al. profile →
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

2021 236 citations Mehmet Samur, Yu‐Tzu Tai et al. profile →
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

2023 77 citations Noopur Raje, Kenneth C. Anderson et al. profile →
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

2024 45 citations Kenneth C. Anderson et al. profile →

Peers

Countries citing papers authored by Kenneth C. Anderson

Since Specialization

Citations

This map shows the geographic impact of Kenneth C. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth C. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth C. Anderson more than expected).

Fields of papers citing papers by Kenneth C. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth C. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth C. Anderson. The network helps show where Kenneth C. Anderson may publish in the future.

Co-authorship network of co-authors of Kenneth C. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth C. Anderson. A scholar is included among the top collaborators of Kenneth C. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth C. Anderson. Kenneth C. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression 2021 ·Clinical Cancer Research ·Lijie Xing, Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen, Yuyin Li, Liang Lin, Phillip A. Hsieh, Shih‐Feng Cho, Gang An, Lugui Qiu, Krista Kinneer, Nikhil C. Munshi, Kenneth C. Anderson, Yu‐Tzu Tai	22
2	Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a 2020 ·Molecular Cancer Research ·Tengteng Yu, (unknown), Xiaoke Ma, Weiwei Sui, Zhen Yu, Lanting Liu, Lei Zhao, (unknown), Jie Xu, Xiaojing Wei, Wen Zhou, Shuhui Deng, Dehui Zou, Gang An, Yu‐Tzu Tai, Guido Tricot, Kenneth C. Anderson, Lugui Qiu, Fenghuang Zhan, Mu Hao	21
3	SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads 2018 ·Clinical Cancer Research ·Krista Kinneer, John Meekin, Arnaud Tiberghien, Yu‐Tzu Tai, Sandrina Phipps, Christine Mione Kiefer, Marlon C. Rebelatto, Nazzareno Dimasi, Alyssa Moriarty, Kyriakos P. Papadopoulos, Sriram Sridhar, Stephen J. Gregson, Michael J. Wick, Luke A. Masterson, Kenneth C. Anderson, Ronald Herbst, Philip W. Howard, David A. Tice	58
4	Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma 2017 ·Clinical Cancer Research ·M. Sagawa, Hiroto Ohguchi, Takeshi Harada, Mehmet Samur, Yu‐Tzu Tai, Nikhil C. Munshi, Masahiro Kizaki, Teru Hideshima, Kenneth C. Anderson	30
5	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma 2016 ·Clinical Cancer Research ·Noopur Raje, Edward A. Faber, Paul G. Richardson, Gary J. Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan P. Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher Kaiser, Damien M. Cronier, James E. Wooldridge, Kenneth C. Anderson	22
6	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 2015 ·Cancer Discovery ·Francesca Cottini, Teru Hideshima, Rikio Suzuki, Yu‐Tzu Tai, Giampaolo Bianchini, Paul G. Richardson, Kenneth C. Anderson, Giovanni Tonon	87
7	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 2015 ·Clinical Cancer Research ·Annamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, Eugenio Morelli, Nicola Amodio, Cirino Botta, Maria Rita Pitari, (unknown), Domenico Britti, Maria Angelica Stamato, Teru Hideshima, Nikhil C. Munshi, Kenneth C. Anderson, Pierosandro Tagliaferri, Pierfrancesco Tassone	97
8	Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma 2014 ·Molecular Cancer Therapeutics ·Diana Cirstea, Loredana Santo, Teru Hideshima, Homare Eda, Yuko Mishima, Neeharika Nemani, Anuj Mahindra, Andrew J. Yee, Güllü Görgün, Yiguo Hu, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M. Guichard, Kenneth C. Anderson, Noopur Raje	24
9	miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway 2014 ·Cancer Research ·Jianjun Zhao, Jianhong Lin, Di Zhu, Xujun Wang, Daniel J. Brooks, Ming Chen, (unknown), Kohichi Takada, Bryan Ciccarelli, (unknown), Jianguo Tao, Yu‐Tzu Tai, Steven P. Treon, Geraldine Pinkus, Winston Patrick Kuo, Teru Hideshima, Mary Bouxsein, Nikhil C. Munshi, Kenneth C. Anderson, Ruben D. Carrasco	159
10	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition 2014 ·Cancer Research ·Naoya Mimura, Teru Hideshima, Toshiyasu Shimomura, Rikio Suzuki, Hiroto Ohguchi, (unknown), Shohei Kikuchi, Yasuhiro Yoshida, Francesca Cottini, Jana Jakubı́ková, Diana Cirstea, Güllü Görgün, Jiro Minami, Yu‐Tzu Tai, Paul G. Richardson, Teruhiro Utsugi, Atsushi Iwama, Kenneth C. Anderson	66
11	In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells 2013 ·Clinical Cancer Research ·Dharminder Chauhan, Arghya Ray, Kristina Viktorsson, Jack Spira, Claudia E. Paba‐Prada, Nikhil Munshi, Paul Richardson, Rolf Lewensohn, Kenneth C. Anderson	79
12	Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma 2012 ·Molecular Cancer Therapeutics ·Douglas W. McMillin, Hannah M. Jacobs, Jake Delmore, Leutz Buon, Zachary R. Hunter, (unknown), Jie Yu, Peter G. Smith, Paul G. Richardson, Kenneth C. Anderson, Steven P. Treon, Andrew L. Kung, Constantine S. Mitsiades	46
13	Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma 2012 ·Clinical Cancer Research ·Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun‐Young Kong, Güllü Görgün, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu‐Tzu Tai, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson	66
14	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia 2010 ·Journal of Clinical Oncology ·Irene M. Ghobrial, Morie A. Gertz, Betsy LaPlant, John Camoriano, Suzanne R. Hayman, Martha Q. Lacy, Stacey Chuma, Brianna Harris, Renee Leduc, Meghan Rourke, Stephen M. Ansell, Daniel J. DeAngelo, Angela Dispenzieri, Leif Bergsagel, Craig B. Reeder, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Thomas E. Witzig	102
15	Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia 2009 ·Clinical Cancer Research ·Hai T. Ngo, Abdel Kareem Azab, Mena Farag, Xiaoying Jia, (unknown), Judith Runnels, Aldo M. Roccaro, Feda Azab, Antonio Sacco, Xavier Leleu, Kenneth C. Anderson, Irene M. Ghobrial	15
16	Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib 2009 ·Clinical Cancer Research ·Melissa Ooi, Patrick Hayden, Vassiliki Kotoula, Douglas W. McMillin, Elpida Charalambous, (unknown), Noopur Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Leutz Buon, Martin Clynes, Peter O’Gorman, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades	53
17	Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma 2009 ·Cancer Research ·Jing Zhang, Martin Sattler, Giovanni Tonon, Clemens Grabher, Samir Lababidi, (unknown), Marc S. Raab, Sonia Vallet, Yiming Zhou, (unknown), Teru Hideshima, Yu‐Tzu Tai, Dharminder Chauhan, Kenneth C. Anderson, Klaus Podar	76
18	Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 2009 ·Cancer Research ·Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicholas Mitsiades, Jana Jakubı́ková, Sauveur-Michel Maira, Carlos Garcı́a-Echeverrı́a, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades	105
19	Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma 2007 ·Cancer Research ·Klaus Podar, Marc S. Raab, Giovanni Tonon, Martin Sattler, Daniela Barilá, Jing Zhang, Yu‐Tzu Tai, Hiroshi Yasui, Noopur Raje, Ronald A. DePinho, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson	55
20	Abtracts Diagnosis, assessment, and reviews 2003 ·Journal of Pain ·Robert N. Jamison, Jeff Schein, S. Vallow, Susan M. Ascher, G. Vorsanger, N. Katz, (unknown), Kenneth C. Anderson, Tito R. Mendoza, (unknown), Charles S. Cleeland, Prabhav K. Tella, Jennifer A. Haythornthwaite, Mitchell B. Max, Shahzad G. Raja, (unknown), Kate L. Lapane, John N. Morris, Lewis A. Lipsitz, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact